Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism

17 Dec 2018

Abstract excerpt

PURPOSE: Dopamine receptor D2 (DRD2) is a G protein-coupled receptor antagonized by ONC201, an anticancer small molecule in clinical trials for high-grade gliomas and other malignancies. DRD5 is a dopamine receptor family member that opposes DRD2 signaling. We investigated the expression of these dopamine receptors in cancer and their influence on tumor cell sensitivity to ONC201. EXPERIMENTAL DESIGN: The Cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Cancer, Stress, Anesthesia, and Immune Response
Share to Glioma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30559168
DOI: 10.1158/1078-0432.ccr-18-2572

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 AntagonismPMID 30559168Read ↗

Epidermal growth factor receptor as a molecular determinant of glioblastoma response to dopamine receptor D2 inhibitorsSemantic proximity Read ↗

Dopamine receptor D2 regulates glioblastoma survival and death through MET and death receptor 4/5Semantic proximity Read ↗

Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastomaSemantic proximity Read ↗

Biological activity of weekly ONC201 in adult recurrent glioblastoma patients.Semantic proximity Read ↗

Synergistic Effects of the DRD2/3 Antagonist ONC201 and Radiation in GlioblastomaSemantic proximity Read ↗

Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomasSemantic proximity Read ↗

Activation of dopamine receptor 2 (DRD2) prompts transcriptomic and metabolic plasticity in glioblastomaSemantic proximity Read ↗

Targeting dopamine receptor D2 as a novel therapeutic strategy in endometrial cancerSemantic proximity Read ↗

Discovery, evaluation and mechanism study of WDR5-targeted small molecular inhibitors for neuroblastomaSemantic proximity Read ↗

DRD4 promotes chemo-resistance and cancer stem cell-like phenotypes by mediating the activation of the Akt/β-catenin signaling axis in liver cancer.Semantic proximity Read ↗

DRD1 suppresses cell proliferation and reduces EGFR activation and PD‐L1 expression in NSCLCSemantic proximity Read ↗

Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.